Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • RSS feeds
Research

Canadian status of “drugs to avoid” in 2017: a descriptive analysis

Joel Lexchin
September 28, 2018 6 (3) E430-E435; DOI: https://doi.org/10.9778/cmajo.20180049
Joel Lexchin
School of Health Policy and Management, York University; University Health Network; Faculty of Medicine, University of Toronto, Toronto, Ont.
MSc MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Information

vol. 6 no. 3 E430-E435
DOI 
https://doi.org/10.9778/cmajo.20180049
PubMed 
30266781
History 
  • Published online September 28, 2018.
Copyright & Usage 
Copyright 2018, Joule Inc. or its licensors

Author Information

  1. Joel Lexchin, MSc MD
  1. School of Health Policy and Management, York University; University Health Network; Faculty of Medicine, University of Toronto, Toronto, Ont.
  1. Correspondence to: Joel Lexchin, jlexchin{at}yorku.ca
View Full Text

Usage statistics: September 2018 to September 2025

AbstractFullPdf
Sep 2018356511
Oct 201810210146
Nov 201826145
Dec 20181563
Jan 201911110
Feb 20199166
Mar 20198107
Apr 201915167
May 2019885
Jun 20191954
Jul 2019835
Aug 2019765
Sep 2019831
Oct 2019632
Nov 2019975
Dec 2019671
Jan 2020243
Feb 20203110
Mar 2020843
Apr 2020653
May 20201131
Jun 20201034
Jul 2020912
Aug 2020775
Sep 20201021
Oct 20201763
Nov 2020883
Dec 20201359
Jan 202110102
Feb 20219145
Mar 202111104
Apr 2021581
May 2021989
Jun 20211354
Jul 20213193
Aug 2021163
Sep 20212126
Oct 202121315
Nov 202122112
Dec 2021181
Jan 2022384
Feb 2022360
Mar 2022254
Apr 20221175
May 20226128
Jun 202242215
Jul 20225103
Aug 2022194
Sep 20226117
Oct 20225104
Nov 2022482
Dec 2022721
Jan 20235115
Feb 2023141
Mar 2023052
Apr 2023156
May 2023371
Jun 20231126
Jul 2023486
Aug 2023242
Sep 2023061
Oct 202301211
Nov 20232131
Dec 2023102313
Jan 20242145
Feb 2024834
Mar 20241235
Apr 20243138
May 20242684
Jun 20243196
Jul 202412110
Aug 20240369
Sep 202426414
Oct 202423416
Nov 202402518
Dec 202411616
Jan 202501216
Feb 202501911
Mar 202506531
Apr 202507524
May 202507024
Jun 202513822
Jul 2025240039
Aug 202542226
Sep 20251914
PreviousNext
Back to top

In this issue

CMAJ Open: 6 (3)
Vol. 6, Issue 3
1 Jul 2018
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Canadian status of “drugs to avoid” in 2017: a descriptive analysis
(Your Name) has sent you a message from CMAJ Open
(Your Name) thought you would like to see the CMAJ Open web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Canadian status of “drugs to avoid” in 2017: a descriptive analysis
Joel Lexchin
Jul 2018, 6 (3) E430-E435; DOI: 10.9778/cmajo.20180049

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Canadian status of “drugs to avoid” in 2017: a descriptive analysis
Joel Lexchin
Jul 2018, 6 (3) E430-E435; DOI: 10.9778/cmajo.20180049
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
  • 'Drugs to avoid: can we improve prescribing appropriateness?
  • Google Scholar

Similar Articles

Collections

  • Clinical
    • Drugs
      • Regulation

Content

  • Current issue
  • Past issues
  • Collections

About

  • General Information
  • Staff
  • Editorial Board
  • Advisory Panel
  • Contact Us
  • Reprints
  • Copyright and Permissions
CMAJ Group

Copyright 2025, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

CMA Civility, Accessibility, Privacy

 

 

Powered by HighWire